Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014 (2014), Article ID 156276, 12 pages
http://dx.doi.org/10.1155/2014/156276
Research Article

Finding Inhibitors of Mutant Superoxide Dismutase-1 for Amyotrophic Lateral Sclerosis Therapy from Traditional Chinese Medicine

1Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, College of Pharmacy, China Medical University, Taichung 40402, Taiwan
2School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
3Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan
4School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan

Received 10 January 2014; Revised 6 February 2014; Accepted 6 February 2014; Published 18 May 2014

Academic Editor: Fuu-Jen Tsai

Copyright © 2014 Hung-Jin Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. H. Brown Jr., “SOD1 aggregates in ALS: cause, correlate or consequence?” Nature Medicine, vol. 4, no. 12, pp. 1362–1364, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Wang, B. Popko, and R. P. Roos, “An enhanced integrated stress response ameliorates mutant SOD1-induced ALS,” Human Molecular Genetics, vol. 23, no. 10, pp. 2629–2638, 2014. View at Publisher · View at Google Scholar
  3. A. A. Brasil, A. Belati, S. C. Mannarino, A. D. Panek, E. C. A. Eleutherio, and M. D. Pereira, “The involvement of GSH in the activation of human Sod1 linked to FALS in chronologically aged yeast cells,” FEMS Yeast Research, vol. 13, no. 5, pp. 433–440, 2013. View at Publisher · View at Google Scholar
  4. D. R. Rosen, T. Siddique, D. Patterson et al., “Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis,” Nature, vol. 362, no. 6415, pp. 59–62, 1993. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Tandan and W. G. Bradley, “Amyotrophic lateral sclerosis: part I. Clinical features, pathology, and ethical issues in management,” Annals of Neurology, vol. 18, no. 3, pp. 271–280, 1985. View at Google Scholar · View at Scopus
  6. R. Tandan and W. G. Bradley, “Amyotrophic lateral sclerosis: part 2. Etiopathogenesis,” Annals of Neurology, vol. 18, no. 4, pp. 419–431, 1985. View at Google Scholar · View at Scopus
  7. K. A. Staats, L. van Helleputte, A. R. Jones et al., “Genetic ablation of phospholipase C delta 1 increases survival in SOD1(G93A) mice,” Neurobiology of Disease, vol. 60, pp. 11–17, 2013. View at Publisher · View at Google Scholar
  8. S. Shinde, N. Arora, and U. Bhadra, “A complex network of micrornas expressed in brain and genes associated with amyotrophic lateral sclerosis,” International Journal of Genomics, vol. 2013, Article ID 383024, 12 pages, 2013. View at Publisher · View at Google Scholar
  9. A. Al-Chalabi and O. Hardiman, “The epidemiology of ALS: a conspiracy of genes, environment and time,” Nature Reviews Neurology, vol. 9, no. 11, pp. 617–628, 2013. View at Publisher · View at Google Scholar
  10. J. S. Valentine and P. J. Hart, “Misfolded CuZnSOD and amyotrophic lateral sclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3617–3622, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Ip, V. K. Mulligan, and A. Chakrabartty, “ALS-causing SOD1 mutations promote production of copper-deficient misfolded species,” Journal of Molecular Biology, vol. 409, no. 5, pp. 839–852, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Shi, A.-L. Ström, J. Gal, and H. Zhu, “Effects of ALS-related SOD1 mutants on dynein- and KIF5-mediated retrograde and anterograde axonal transport,” Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1802, no. 9, pp. 707–716, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Zinman, H. N. Liu, C. Sato et al., “A mechanism for low penetrance in an ALS family with a novel SOD1 deletion,” Neurology, vol. 72, no. 13, pp. 1153–1159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. F. L. Muller, Y. Liu, A. Jernigan, D. Borchelt, A. Richardson, and H. van Remmen, “MnSOD deficiency has a differential effect on disease progression in two different ALS mutant mouse models,” Muscle and Nerve, vol. 38, no. 3, pp. 1173–1183, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Yoshii, A. Otomo, L. Pan, M. Ohtsuka, and S. Hadano, “Loss of glial fibrillary acidic protein marginally accelerates disease progression in a SOD1H46R transgenic mouse model of ALS,” Neuroscience Research, vol. 70, no. 3, pp. 321–329, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. D. D. Winkler, J. P. Schuermann, X. Cao et al., “Structural and biophysical properties of the pathogenic SOD1 variant H46R/H48Q,” Biochemistry, vol. 48, no. 15, pp. 3436–3447, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Kokubo, S. Kuzuhara, Y. Narita et al., “Accumulation of neurofilaments and SOD1-immunoreactive products in a patient with familial amyotrophic lateral sclerosis with I113T SOD1 mutation,” Archives of Neurology, vol. 56, no. 12, pp. 1506–1508, 1999. View at Google Scholar · View at Scopus
  18. P. G. Ince, P. J. Shaw, J. Y. Slade, C. Jones, and P. Hudgson, “Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes,” Acta Neuropathologica, vol. 92, no. 4, pp. 395–403, 1996. View at Publisher · View at Google Scholar
  19. Y. Honjo, S. Kaneko, H. Ito et al., “Protein disulfide isomerase-immunopositive inclusions in patients with amyotrophic lateral sclerosis,” Amyotrophic Lateral Sclerosis, vol. 12, no. 6, pp. 444–450, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. M. E. Cudkowicz, D. McKenna-Yasek, P. E. Sapp et al., “Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis,” Annals of Neurology, vol. 41, no. 2, pp. 210–221, 1997. View at Publisher · View at Google Scholar
  21. M. Aoki, M. Ogasawara, Y. Matsubara et al., “Familial amytrophic lateral sclerosis (ALS) in Japan associated with H46R mutation in Cu/Zn superoxide dismutase gene: a possible new subtype of familial ALS,” Journal of the Neurological Sciences, vol. 126, no. 1, pp. 77–83, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Nakamura, R. Wate, S. Kaneko et al., “An autopsy case of sporadic amyotrophic lateral sclerosis associated with the I113T SOD1 mutation,” Neuropathology, vol. 34, no. 1, pp. 58–63, 2014. View at Publisher · View at Google Scholar
  23. G. Lopate, R. H. Baloh, M. T. Al-Lozi et al., “Familial ALS with extreme phenotypic variability due to the I113T SOD1 mutation,” Amyotrophic Lateral Sclerosis, vol. 11, no. 1-2, pp. 232–236, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Schmidlin, B. K. Kennedy, and V. Daggett, “Structural changes to monomeric CuZn superoxide dismutase caused by the familial amyotrophic lateral sclerosis-associated mutation A4V,” Biophysical Journal, vol. 97, no. 6, pp. 1709–1718, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. L. I. Bruijn, M. K. Houseweart, S. Kato et al., “Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1,” Science, vol. 281, no. 5384, pp. 1851–1854, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. J. R. Auclair, K. J. Boggio, G. A. Petsko, D. Ringe, and J. N. Agar, “Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 50, pp. 21394–21399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S.-S. Chang, H.-J. Huang, and C. Y.-C. Chen, “High performance screening, structural and molecular dynamics analysis to identify H1 inhibitors from TCM Database@Taiwan,” Molecular BioSystems, vol. 7, no. 12, pp. 3366–3374, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. C.-Y. Chen, Y.-H. Chang, D.-T. Bau et al., “Ligand-based dual target drug design for H1N1: swine flu—a preliminary first study,” Journal of Biomolecular Structure and Dynamics, vol. 27, no. 2, pp. 171–178, 2009. View at Google Scholar · View at Scopus
  29. T.-T. Chang, M.-F. Sun, H.-Y. Chen et al., “Screening from the world's largest TCM database against H1N1 virus,” Journal of Biomolecular Structure and Dynamics, vol. 28, no. 5, pp. 773–786, 2011. View at Google Scholar · View at Scopus
  30. H.-J. Huang, H. W. Yu, C.-Y. Chen et al., “Current developments of computer-aided drug design,” Journal of the Taiwan Institute of Chemical Engineers, vol. 41, no. 6, pp. 623–635, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. I. C. Chou, W.-D. Lin, C.-H. Wang et al., “Möbius syndrome in a male with XX/XY mosaicism,” BioMedicine, vol. 3, no. 2, pp. 102–104, 2013. View at Publisher · View at Google Scholar
  32. I. C. Chou, W.-D. Lin, C.-H. Wang et al., “Association analysis between Tourette's syndrome and two dopamine genes (DAT1, DBH) in Taiwanese children,” BioMedicine, vol. 3, no. 2, pp. 88–91, 2013. View at Publisher · View at Google Scholar
  33. C.-C. Lee, C.-H. Tsai, L. Wan et al., “Increased incidence of Parkinsonism among Chinese with β-glucosidase mutation in central Taiwan,” BioMedicine, vol. 3, no. 2, pp. 92–94, 2013. View at Publisher · View at Google Scholar
  34. C.-H. Wang, W.-D. Lin, D.-T. Bau et al., “Appearance of acanthosis nigricans may precede obesity: an involvement of the insulin/IGF receptor signaling pathway,” BioMedicine, vol. 3, no. 2, pp. 82–87, 2013. View at Publisher · View at Google Scholar
  35. C.-H. Wang, W.-D. Lin, and F.-J. Tsai, “Craniofacial dysmorphism, what is your diagnosis?” BioMedicine, vol. 2, no. 2, pp. 49–50, 2012. View at Publisher · View at Google Scholar
  36. W.-Y. Lin, H.-P. Liu, J.-S. Chang et al., “Genetic variations within the PSORS1 region affect Kawasaki disease development and coronary artery aneurysm formation,” BioMedicine, vol. 3, no. 2, pp. 73–81, 2013. View at Publisher · View at Google Scholar
  37. C. Y.-C. Chen, “Weighted equation and rules—a novel concept for evaluating protein-ligand interaction,” Journal of Biomolecular Structure and Dynamics, vol. 27, no. 3, pp. 271–282, 2009. View at Google Scholar · View at Scopus
  38. T.-Y. Tsai, K.-W. Chang, and C. Y.-C. Chen, “IScreen: world's first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan,” Journal of Computer-Aided Molecular Design, vol. 25, no. 6, pp. 525–531, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. H.-J. Huang, Y.-R. Jian, and C.-Y. Chen, “Traditional Chinese medicine application in HIV: an in silico study,” Journal of Biomolecular Structure and Dynamics, vol. 32, no. 1, pp. 1–12, 2014. View at Publisher · View at Google Scholar
  40. S.-S. Chang, H.-J. Huang, and C. Y.-C. Chen, “Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine,” PLoS Computational Biology, vol. 7, no. 12, Article ID e1002315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. K.-C. Chen, M.-F. Sun, S.-C. Yang et al., “Investigation into potent inflammation inhibitors from traditional Chinese medicine,” Chemical Biology and Drug Design, vol. 78, no. 4, pp. 679–688, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. S.-C. Yang, S.-S. Chang, H.-Y. Chen, and C. Y.-C. Chen, “Identification of potent EGFR inhibitors from TCM Database@Taiwan,” PLoS Computational Biology, vol. 7, no. 10, Article ID e1002189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. S.-C. Yang, S.-S. Chang, and C. Y.-C. Chen, “Identifying HER2 inhibitors from natural products database,” PLoS ONE, vol. 6, no. 12, Article ID e28793, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. A. Tsou, K. C. Chen, H. C. Lin, S. S. Chang, and C. Y. Chen, “Uroporphyrinogen decarboxylase as a potential target for specific components of traditional Chinese medicine: a virtual screening and molecular dynamics study,” PLoS ONE, vol. 7, no. 11, Article ID e50087, 2012. View at Publisher · View at Google Scholar
  45. C.-Y. Chen and C. Y.-C. Chen, “Insights into designing the dual-targeted HER2/HSP90 inhibitors,” Journal of Molecular Graphics and Modelling, vol. 29, no. 1, pp. 21–31, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Y.-C. Chen, Y.-F. Chen, C.-H. Wu, and H.-Y. Tsai, “What is the effective component in suanzaoren decoction for curing insomnia? Discovery by virtual screening and molecular dynamic simulation,” Journal of Biomolecular Structure and Dynamics, vol. 26, no. 1, pp. 57–64, 2008. View at Google Scholar · View at Scopus
  47. K. C. Chen, S. S. Chang, H. J. Huang et al., “Three-in-one agonists for PPAR-alpha, PPAR-gamma, and PPAR-delta from traditional Chinese medicine,” Journal of Biomolecular Structure and Dynamics, vol. 30, no. 6, pp. 662–683, 2012. View at Google Scholar
  48. C. Y.-C. Chen, “Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database,” Journal of Biomolecular Structure and Dynamics, vol. 27, no. 5, pp. 627–640, 2010. View at Google Scholar · View at Scopus
  49. C.-Y. Chen, Y.-H. Chang, D.-T. Bau et al., “Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis,” Acta Pharmacologica Sinica, vol. 30, no. 8, pp. 1186–1194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Y.-C. Chen, “Computational screening and design of Traditional Chinese Medicine (TCM) to block phosphodiesterase-5,” Journal of Molecular Graphics and Modelling, vol. 28, no. 3, pp. 261–269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. K.-C. Chen, K.-W. Chang, H.-Y. Chen, and C. Y.-C. Chen, “Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once?” Molecular BioSystems, vol. 7, no. 9, pp. 2711–2719, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Y. Chen, S. S. Chang, Y. C. Chan, and C. Y. Chen, “Discovery of novel insomnia leads from screening traditional Chinese medicine database,” Journal of Biomolecular Structure and Dynamics, vol. 32, no. 5, pp. 776–791, 2014. View at Publisher · View at Google Scholar
  53. C. Y. Chen, “Mechanism of BAG1 repair on Parkinson's disease-linked DJ1 mutation,” Journal of Biomolecular Structure and Dynamics, vol. 30, no. 1, pp. 1–12, 2012. View at Publisher · View at Google Scholar
  54. Y.-M. Chang, B. K. Velmurugan, W.-W. Kuo et al., “Inhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cells,” BioMedicine, vol. 3, no. 4, pp. 148–152, 2013. View at Google Scholar
  55. P.-C. Lin, P.-Y. Liu, S.-Z. Lin, and H.-J. Harn, “Angelica sinensis: a Chinese herb for brain cancer therapy,” BioMedicine, vol. 2, no. 1, pp. 30–35, 2012. View at Publisher · View at Google Scholar
  56. T.-Y. Ho, H.-Y. Lo, C.-C. Li, J.-C. Chen, and C.-Y. Hsiang, “In vitro and in vivo bioluminescent imaging to evaluate anti-Escherichia coli activity of Galla Chinensis,” BioMedicine, vol. 3, no. 4, pp. 160–166, 2013. View at Publisher · View at Google Scholar
  57. C.-C. Li, H.-Y. Lo, C.-Y. Hsiang, and T.-Y. Ho, “DNA microarray analysis as a tool to investigate the therapeutic mechanisms and drug development of Chinese medicinal herbs,” BioMedicine, vol. 2, no. 1, pp. 10–16, 2012. View at Publisher · View at Google Scholar
  58. S.-C. Hsu and J.-G. Chung, “Anticancer potential of emodin,” BioMedicine, vol. 2, no. 3, pp. 108–116, 2012. View at Publisher · View at Google Scholar
  59. C. Y.-C. Chen, “TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico,” PLoS ONE, vol. 6, no. 1, Article ID e15939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. G. S. Wright, S. V. Antonyuk, N. M. Kershaw, R. W. Strange, and S. S. Hasnain, “Ligand binding and aggregation of pathogenic SOD1,” Nature Communications, vol. 4, article 1758, 2013. View at Publisher · View at Google Scholar
  61. Accelerys, Discovery Studio Client V2.5, Accelrys, San Diego, Calif, USA, 2009.
  62. B. Xue, R. L. Dunbrack, R. W. Williams, A. K. Dunker, and V. N. Uversky, “PONDR-FIT: a meta-predictor of intrinsically disordered amino acids,” Biochimica et Biophysica Acta: Proteins and Proteomics, vol. 1804, no. 4, pp. 996–1010, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Zhao, C. P. Kao, Y. S. Chang, and Y. L. Ho, “Quality assessment on Polygoni Multiflori Caulis using HPLC/UV/MS combined with principle component analysis,” Chemistry Central Journal, vol. 7, no. 1, article 106, 2013. View at Publisher · View at Google Scholar
  64. N. L. Allinger, “Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms,” Journal of the American Chemical Society, vol. 99, no. 25, pp. 8127–8134, 1977. View at Google Scholar · View at Scopus
  65. C. M. Venkatachalam, X. Jiang, T. Oldfield, and M. Waldman, “LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites,” Journal of Molecular Graphics and Modelling, vol. 21, no. 4, pp. 289–307, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. B. R. Brooks, R. E. Bruccoleri, B. D. Olafson, D. J. States, S. Swaminathan, and M. Karplus, “CHARMM: a program for macromolecular energy, minimization, and dynamics calculations,” Journal of Computational Chemistry, vol. 4, no. 2, pp. 187–217, 1983. View at Publisher · View at Google Scholar
  67. R. Fletcher and C. M. Reeves, “Function minimization by conjugate gradients,” The Computer Journal, vol. 7, no. 2, pp. 149–154, 1964. View at Publisher · View at Google Scholar
  68. W. H. Press, B. P. Flannery, S. A. Teukolsky, W. T. Vetterling, and H. Gould, “Numerical recipes, the art of scientific computing,” American Journal of Physics, vol. 55, no. 1, pp. 90–91, 1987. View at Google Scholar
  69. S. Pronk, S. Pall, R. Schulz et al., “GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit,” Bioinformatics, vol. 29, no. 7, pp. 845–854, 2013. View at Publisher · View at Google Scholar
  70. W. I. Tou, S. S. Chang, C. C. Lee, and C. Y.-C. Chen, “Drug design for neuropathic pain regulation from traditional Chinese medicine,” Scientific Reports, vol. 3, article 844, 2013. View at Publisher · View at Google Scholar
  71. W. I. Tou and C. Y. Chen, “May disordered protein cause serious drug side effect?” Drug Discovery Today, vol. 19, no. 4, pp. 367–372, 2014. View at Publisher · View at Google Scholar